Compare RPID & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | GANX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 76.8M |
| IPO Year | 2021 | 2021 |
| Metric | RPID | GANX |
|---|---|---|
| Price | $0.78 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.75 | ★ $7.20 |
| AVG Volume (30 Days) | 199.4K | ★ 647.2K |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.78 | ★ 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,587,000.00 | $55,180.00 |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $17.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.74 | N/A |
| 52 Week Low | $0.76 | $1.15 |
| 52 Week High | $4.94 | $4.34 |
| Indicator | RPID | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 26.99 | 26.05 |
| Support Level | $0.76 | N/A |
| Resistance Level | $2.18 | $2.01 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 8.53 | 2.78 |
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.